DOCKET NO.: ISIS-1158

PATENT

RECEIVED S 1998 GROUP 1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

patent application of:

Buchardt et al.

Serial No.:

08/319,411

Group No.: 1809

Filed:

October 6, 1994

Examiner: A. Marschel

For:

PEPTIDE NUCLEIC ACID CONJUGATES

I, Michael P. Straher Registration No. 38,325 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On January 28, 1998

Michael P. Straher Registration No. 38,325

Assistant Commissioner for Patents Washington DC 20231

Sir:

## AMENDMENT TRANSMITTAL LETTER

Transmitted herewith is an amendment in the aboveidentified application responsive to the Office Action dated October 28, 1997.

- ( ) Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- ( ) A verified statement claiming small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- ( ) Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR §§ 1.821 through 1.825.
- ( ) No additional fee is required.

The fee for additional claims presented in this amendment has been calculated as follows:

			SMALL ENTITY			OTHER THAN SMALL ENTITY		
The second of th	Claims Remaining After Amendment	Highest Number Previously Paid for	No. Extra	Rate	Fee	<u>OR</u>	Rate	Fee
Total Claims	38 + 11	38 = (at least 20)	0	x\$11=	\$	<u>OR</u>	x\$22=	\$0
Indep. Claims	15	4= (at least 3)	11	x\$40=	\$	<u>OR</u>	x\$80=	\$880
First Presentation Multiple Dependent Claims + \$130=					\$	<u>OR</u>	\$260=	\$0
Total fee for added claims:					\$			\$880

- (XX) Please charge my Deposit Account No. 23-3050 in the amount of \$ 880.00. This sheet is attached in triplicate.
- ( ) A check in the amount of \$\_\_\_\_ is attached. Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.
- (XX) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in triplicate.
  - (XX) Any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims.
  - (XX) Any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).
- (XX) The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in triplicate.
  - (XX) Any patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).

( ) The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).

(XX) Any filing fees under 37 CFR 1.16 including fees for presentation of extra claims.

Date: January 28, 1998

Michael P. Straher

Registration No. 38,325

WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 (215) 568-3100

NO.: ISIS-1158

RESPONSE UNDER 37 CFR 1.116 EXPEDITED PROCEDURE **EXAMINING GROUP 1809** 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:

Nielsen, et al.

Serial No.: 08/319,411

Filed: October 6, 1994

For: PEPTIDE NUCLEIC ACID CONJUGATES

Group Art Unit: 1809

Examiner: A. Marschel

I, Michael P. Straher Registration No. 38,325 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On January 28, 1998

Michael P. Straher Registration No. 38,325

Box AF Assistant Commissioner for Patents Washington, D.C. 20231

## REQUEST FOR RECONSIDERATION

In response to the Office Action mailed October 28, 1997, in connection with the above-captioned patent application, Applicants respectfully request that the following amendment be entered:

In the claims:

298 MPEOPLES 00000031 DAM:233050 cosspen claims 11, 14, 16, 25-29, and 34-36.

Please amend claims 1, 5, 30, 37 and 38 as indicated below:

(Twice amended) A peptide nucleic acid conjugate 1.

comprising:

a peptide nucleic acid;